Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Front Immunol. 2022 Dec 8;13:1058272. doi: 10.3389/fimmu.2022.1058272. eCollection 2022.
The gut commensal microbes modulate human immunity and metabolism through the production of a large number of metabolites, which act as signaling molecules and substrates of metabolic reactions in a diverse range of biological processes. There is a growing appreciation for the importance of immunometabolic mechanisms of the host-gut microbiota interactions in various malignant tumors. Emerging studies have suggested intestinal microbiota contributes to the progression of multiple myeloma. In this review, we summarized the current understanding of the gut microbiome in MM progression and treatment, and the influence of alterations in gut microbiota on treatment response and treatment-related toxicity and complications in MM patients undergoing hematopoietic stem cell transplantation (HSCT). Furthermore, we discussed the impact of gut microbiota-immune system interactions in tumor immunotherapy, focusing on tumor vaccine immunotherapy, which may be an effective approach to improve anti-myeloma efficacy.
肠道共生微生物通过产生大量代谢物来调节人体的免疫和代谢,这些代谢物作为信号分子和代谢反应的底物,在多种生物过程中发挥作用。人们越来越认识到宿主-肠道微生物群相互作用的免疫代谢机制在各种恶性肿瘤中的重要性。新兴的研究表明,肠道微生物群有助于多发性骨髓瘤的进展。在这篇综述中,我们总结了目前对 MM 进展和治疗中肠道微生物组的理解,以及肠道微生物组的改变对接受造血干细胞移植 (HSCT) 的 MM 患者的治疗反应、治疗相关毒性和并发症的影响。此外,我们讨论了肠道微生物群-免疫系统相互作用在肿瘤免疫治疗中的影响,重点是肿瘤疫苗免疫治疗,这可能是提高抗骨髓瘤疗效的一种有效方法。